SPOTLIGHT -
Olaparib Trial Supports 2-Year Treatment Duration in Ovarian Cancer
William H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.
